Rapport COO sells 10,000 shares in planned trade

Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported selling a total of 10,000 shares of Common Stock in open-market transactions.

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. Chief Operating Officer Cheryl Gault reported selling a total of 10,000 shares of Common Stock in open-market transactions. She sold 7,161 shares at a weighted average price of $28.0401 and 2,839 shares at a weighted average price of $28.5530. After these sales, she directly holds 159,914 shares. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.

Insider Trade Summary 10b5-1

Net Seller: 10,000 shares

Net Sell 2 txns

Insider Gault Cheryl

Role Chief Operating Officer

Sold 10,000 shs ($282K)

Type	Security	Shares	Price	Value
Sale	Common Stock	7,161	$28.0401	$201K
Sale	Common Stock	2,839	$28.553	$81K

Holdings After Transaction: Common Stock — 159,914 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.42 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. F3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.42 to $28.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

Key Figures

Total shares sold: 10,000 shares First tranche sale: 7,161 shares at $28.0401 Second tranche sale: 2,839 shares at $28.5530 +2 more

5 metrics

Total shares sold 10,000 shares Open-market sales on March 30, 2026

First tranche sale 7,161 shares at $28.0401 Weighted average price for Common Stock sale

Second tranche sale 2,839 shares at $28.5530 Weighted average price for Common Stock sale

Shares held after transactions 159,914 shares Direct Common Stock ownership after March 30, 2026 sales

Trading plan adoption date December 10, 2025 Rule 10b5-1 trading plan governing the sales

Key Terms

Rule 10b5-1 trading plan, weighted average price, open-market sale, Common Stock

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

"security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Rapport Therapeutics (RAPP) report for Cheryl Gault?

Rapport Therapeutics reported that Chief Operating Officer Cheryl Gault sold 10,000 shares of Common Stock in open-market transactions. The sales occurred in two tranches on March 30, 2026, as disclosed in a Form 4 insider trading report filed with regulators.

At what prices did Cheryl Gault sell Rapport Therapeutics (RAPP) shares?

Cheryl Gault sold 7,161 shares at a weighted average price of $28.0401 and 2,839 shares at a weighted average price of $28.5530. The filing notes these were averages for multiple trades within narrower intraday price ranges on the transaction date.

How many Rapport Therapeutics (RAPP) shares does Cheryl Gault hold after the sale?

After the reported transactions, Cheryl Gault directly holds 159,914 shares of Rapport Therapeutics Common Stock. This post-transaction balance, shown in the Form 4, indicates she retained a substantial equity position following the 10,000-share open-market sale.

Was the Rapport Therapeutics (RAPP) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025. Such plans pre-schedule trades, signaling the timing of these sales was arranged in advance rather than decided opportunistically.

Who is the insider selling shares of Rapport Therapeutics (RAPP)?

The insider is Cheryl Gault, Chief Operating Officer of Rapport Therapeutics, Inc. As an executive officer, her transactions in the company’s Common Stock must be reported on Form 4, providing public transparency into her equity sales and remaining holdings.

How many Rapport Therapeutics (RAPP) insider sales were disclosed in this Form 4?

The Form 4 shows two separate open-market sale transactions, both on March 30, 2026. Together they total 10,000 shares of Common Stock sold, with each line item reporting its own weighted average sale price and the updated share balance after the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/31/2026 - 04:27 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gault Cheryl

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/30/2026		S(1)		7,161	D	$28.0401(2)	162,753	D
Common Stock	03/30/2026		S(1)		2,839	D	$28.553(3)	159,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on December 10, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.42 to $28.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.42 to $28.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

	/s/ Troy Ignelzi, Attorney-in-Fact	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)